{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-007763","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.226507+00:00","generated_at":"2026-06-18T02:12:52.951212+00:00","sec_items":["1.01","2.03","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AgeX borrows $10M from Juvenescence, lends to Serina; Dr. West resigns from board","bullets":["Entered $10M secured convertible note with Juvenescence; proceeds used to purchase $10M Serina note.","Juvenescence note matures March 2026; 7% origination fee; convertible into AgeX common stock after merger or March 2024.","Dr. Michael D. West resigned from AgeX board but remains CEO; expected to transition to CEO of subsidiary Reverse Bio after spinoff.","Potential merger with Serina and spinoff of Reverse Bio are under consideration but no definitive agreements executed yet."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-007763","json":"https://secwatch.observer/filing/0001493152-23-007763.json","markdown":"https://secwatch.observer/filing/0001493152-23-007763.md","text":"https://secwatch.observer/filing/0001493152-23-007763.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223007763/0001493152-23-007763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223007763/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T02:12:52.951212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"951b4d17a461c5d84e42c58cb7e28b5d32a9de2b","claim":"Serina Therapeutics, Inc. incurred convertible notes of $10,000,000 with Juvenescence Limited at origination fee in an amount equal to 7% of the loan funds disbursed to AgeX maturing March 13, 2026.","evidence_excerpt":"(“ AgeX ”) and Juvenescence Limited (“ Juvenescence ”) entered into a Secured Convertible Promissory Note (the “ Juvenescence Note ”) pursuant to which Juvenescence","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223007763/0001493152-23-007763-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$10,000,000"},{"label":"Counterparty","value":"Juvenescence Limited"},{"label":"Rate","value":"origination fee in an amount equal to 7% of the loan funds disbursed to AgeX"},{"label":"Maturity","value":"March 13, 2026"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"5d024f87c6","claim":"Dr. Michael D. West resigned as Director at Serina Therapeutics, Inc..","evidence_excerpt":"On March 9, 2023, Dr. Michael D. West resigned from AgeX’s Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223007763/0001493152-23-007763-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c76079b083206b7d8e34725429fa8bdf18c5ac16","claim":"Serina Therapeutics, Inc. entered into Convertible Note Purchase Agreement with AgeX Therapeutics, Inc. valued at $10,000,000 (effective 2023-03-15).","evidence_excerpt":"Serina Therapeutics Inc., an Alabama corporation (“ Serina ”) to AgeX on March 15, 2023, pursuant to the terms of a Convertible Note Purchase Agreement, dated March 15, 2023 (the “ Serina Note Purchase Agreement ”), between AgeX and Serina.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223007763/0001493152-23-007763-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"AgeX Therapeutics, Inc."},{"label":"Value","value":"$10,000,000"},{"label":"Effective","value":"2023-03-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}